Pfizer

MusclePharm adds Dr. Richard Ogden to board

Monday, April 11, 2011 12:37 PM

MusclePharm, a Nevada corporation, a U.S. nutritional supplement company, will add Richard Ogden, PhD, to its medical advisory board.

More... »

Zacharon Pharmaceuticals collaborates with Pfizer

Friday, April 8, 2011 10:40 AM

California-based Zacharon Pharmaceuticals has entered into a strategic research collaboration with Pfizer to develop drugs for orphan diseases, including lysosomal storage disorders. The estimated value of the collaboration to Zacharon is $210 million. The collaboration includes the development of compounds that may be discovered using Zacharon's innovative platform for developing small molecule drugs targeting specific carbohydrate polymers or glycans.

More... »

Eisenhart named VP at Northwestern Mutual

Wednesday, April 6, 2011 01:18 PM

Joann Eisenhart, formerly senior vice president of human resources at Pfizer, has been named vice president of human resources of Milwaukee-based Northwestern Mutual.  Eisenhart also was named an executive officer. 

More... »

Pfizer plans to sell Capsugel unit

Tuesday, April 5, 2011 02:57 PM

Pfizer has plans to sell its Capsugel unit to an affiliate of investment firm Kohlberg Kravis Roberts (KKR) for nearly $2.4 billion in cash.  Pfizer’s plans to divest the division to narrow its business focus have been known for a while, according to Pharma Times.

More... »

Drugmakers may face FDA fines for slow efficacy confirmation in cancer drugs

Monday, March 28, 2011 01:04 PM

Winning early U.S. approval of promising cancer treatments could wind up costing drugmakers up to $10 million in fines if they don’t confirm their drugs’ effectiveness in follow-up studies within a restrictive timeframe, FDA officials said, according to a Bloomberg report.

More... »

Quark Pharmaceuticals to initiate phase IIb study

Tuesday, March 22, 2011 12:12 PM

Calif.-based Quark Pharmaceuticals, engaged in the discovery and development of RNAi-based therapeutics, has received results from a prospective randomized phase II trial, the DEGAS study.  This study evaluated the safety and efficacy of PF-04523655 (RTP801I-14) in patients with diabetic macular edema (DME). There were 184 patients randomly assigned to four treatment groups; three dose levels of PF-04523655 (RTP801I-14) (0.4mg, 1mg, and 3mg) or laser. The study was designed with a primary endpoint of mean visual acuity improvements over baseline at 24 months.

More... »

Many trials exclude depressed patients

Tuesday, March 22, 2011 11:20 AM

When the FDA announced in 2009 that Pfizer’s smoking-cessation drug Chantix would need to carry a restrictive "black box" warning label, the move didn't really surprise the market, according to a Reuters report.

More... »

Pfizer to gradually move antibacterials operations to China

Wednesday, March 16, 2011 01:00 PM

Pfizer plans to move its antibacterials research unit in Groton, Conn., to Shanghai, China, but said some local scientists involved in the research will remain in Groton for up to two years as the company builds the new Shanghai unit, according to a report in Connecticut newspaper The Day.

More... »

Pfizer talking with CROs to fill R&D hub

Wednesday, March 16, 2011 12:33 PM

A U.K. task force—assembled to salvage as many R&D jobs at Sandwich as it can before Pfizer completes its planned exit—has confirmed that the pharma giant is in discussions with CROs that may step in to hire some of the 2,400 workers being let go, according to Fierce Biotech.

More... »

Report: Big Pharmas embracing technology as they transform to ‘holistic healthcare entities’

Monday, March 14, 2011 07:00 AM

Pharmaceutical companies—having outsourced R&D functions to CROs and collaborated with biotechs, drug companies and academic groups for innovative products and platforms—are now embracing a different type of innovation: technology.

More... »